In vitro production of anti‐RBC antibodies and cytokines in chronic lymphocytic leukemia

Wilma Barcellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Alberto Zanella(University of Milan), Francesca Guia Imperiali(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Rosanna Montesano(Ospedale Maggiore), Rossella Calori(IRCCS Policlinico San Donato), Anna Zaninoni(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Giacomo Clerici(MultiMedica)
American Journal of Hematology
October 30, 2002
10.1002/ajh.10210
Cited by 42

Related Papers

Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy
|JAMA Internal Medicine|2020|1.7k
Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study
|The Lancet Respiratory Medicine|2020|738
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
|Blood|2009|433
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial
|Journal of Clinical Oncology|2016|394
Peripheral Angioplasty as the First-choice Revascularization Procedure in Diabetic Patients with Critical Limb Ischemia: Prospective Study of 993 Consecutive Patients Hospitalized and Followed Between 1999 and 2003
|European Journal of Vascular and Endovascular Surgery|2005|373